Skip to main content

U.S. Supreme Court Upholds Nitric Oxide Patent Win for Linde; Linde Commits to Support Inhaled Nitric Oxide Clinical Studies Relating to COVID-19

GUILDFORD, UK / ACCESSWIRE / April 8, 2020 / Linde (NYSE:LIN; FWB:LIN), a leading global supplier of inhaled nitric oxide, is pleased with the decision by the U.S. Supreme Court declining to review the 2019 appeals court decision that affirmed Praxair Distribution, Inc.'s (PDI) right to sell a generic form of inhaled nitric oxide. This decision ends the long-running U.S. patent litigation with Mallinckrodt plc, and affirms the ability of PDI, a wholly owned subsidiary of Linde, to continue supplying inhaled nitric oxide. This drug product is widely used as approved in the U.S. and other countries to improve oxygenation of certain groups of patients.

"Nitric oxide is truly a unique and beneficial drug product. We are proud to be doing our part to support healthcare institutions around the world with a reliable, competitive and beneficial supply of inhaled nitric oxide along with our other medical gases and services," said Ben Glazer, President, US Packaged & Specialty Gases.

Linde is actively supporting doctors as they investigate the use of nitric oxide to treat COVID-19 patients globally. This includes supplying nitric oxide to Massachusetts General Hospital to support a trial launched by their researchers to test the drug's effectiveness for preventing disease progression in patients with mild to moderate disease, thereby avoiding the need for ventilation. Separately, German authorities have authorized on a temporary basis the use of inhaled nitric oxide specifically to treat patients with severe cases of COVID-19.

About Linde
Linde is a leading global industrial gases and engineering company with 2019 sales of $28 billion (€25 billion). We live our mission of making our world more productive every day by providing high-quality solutions, technologies and services which are making our customers more successful and helping to sustain and protect our planet.

The company serves a variety of end markets including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing and primary metals. Linde's industrial gases are used in countless applications, from life-saving oxygen for hospitals to high-purity & specialty gases for electronics manufacturing, hydrogen for clean fuels and much more. Linde also delivers state-of-the-art gas processing solutions to support customer expansion, efficiency improvements and emissions reductions.

For more information about the company and its products and services, please visit www.linde.com.

Contacts: 
Investor Relations
Juan Pelaez
Phone: +1 203 837 2213
Email: juan.pelaez@linde.com
Media Relations
Anna Davies
Phone: +44 1483 244705
Email: anna.davies@linde.com

SOURCE: Linde plc



View source version on accesswire.com:
https://www.accesswire.com/584386/US-Supreme-Court-Upholds-Nitric-Oxide-Patent-Win-for-Linde-Linde-Commits-to-Support-Inhaled-Nitric-Oxide-Clinical-Studies-Relating-to-COVID-19

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.